[email protected] +1 646 480 7505 (U.S.) | +44 203 318 2846 (U.K.)

Global Statistics Representing Uterine Cancer Market Scenario

Women of age between 42 and 50 experiencing menopause or post menopause, are more susceptible to be diagnosed and suffer through uterine cancer. It starts in the endometrium, which is a lining of uterus and proceeds to uterus and neighboring tissues and then to the whole body. Exact causes of the uterine cancer is still unknown and early diagnosis is roughly possible due to very common symptoms such as casual bleeding and others. Among four types of the uterine cancer, papillary serous carcinoma is most dangerous and aggressive as it tends to return even when it is diagnosed early and treated. Moreover, uterine sarcoma starts in the myometrium, uterine muscle wall and spreads to whole uterus and it tends to spread to lungs through bloodstream.

High and increasing prevalence of the uterine cancer is the major factor driving the global uterine cancer market. According to the World Cancer Research Fund International, prevalence rate of the uterine cancer per 100,000 women is high across the globe in major countries including Belarus has 24.9 rate, Samoa has 24.8, Canada has 23.6, the U.S. 20.1, Poland has 19.1, Singapore has 19.1, Russia has 18.7, and Puerto Rico has 17.4. Ongoing research and development regarding diagnostics and treatment of the uterine cancer is the other factor which is expected to escalate the market growth during the forecast period 2019–2026.

However, poor healthcare infrastructure across the Latin America and Africa is expected to restrain the market growth. Lack of advancements in the diagnostics in some region and scarcity of skilled diagnostics professionals are some of the other factors which are expected to hamper the market growth further. Unavailability of the reimbursement policies may slow the market growth during the forecast period 2019–2026.

Global endometrial cancer market is expected to register a CAGR of 4.7% over the forecast period 2019-2026.

Segmental Insights

The global uterine cancer market is segmented into type, treatment, end user, and region.

Based on type the global uterine cancer market is segmented into endometrial adenocarcinoma, adenosquamous carcinoma, papillary serous carcinoma, and uterine sarcoma. Amongst type, endometrial adenocarcinoma segment accounts for major share of the global uterine cancer market. Adenosquamous carcinoma is expected to grow steadily during the forecast period 2019–2026.

On the basis of treatment, the market is segmented into diagnosis, therapeutic treatment, and surgery. Diagnosis is further segmented into Pelvic examination, endometrial biopsy, transvaginal ultrasound, computed tomography (CT or CAT) scan, and magnetic resonance imaging (MRI). Therapeutic treatment is segregated into radiation therapy, chemotherapy, and hormone therapy. Surgery is further divided into hysterectomy and lymphadenectomy. Amongst treatment, therapeutic treatment segment is expected to account for largest share of the market owing to the ongoing research and development regarding improvement in the treatments for uterine cancer. Surgery is expected to experience significant growth over the forecast period 2019–2026.

Based on end user, the market is segmented into hospitals, diagnostic centers, drug stores, online pharmacies, and other end users. Hospitals segment is expected to dominate the market and grow swiftly owing to the advancements in the hospital infrastructures and services. Effective treatment and diagnosis in hospitals is the other factor expected to fuel the market growth over the forecast period 2019–2026.

Regional Insights

In terms of region the global uterine cancer market is segmented into North America, Europe, Asia Pacific, Latin America and the Middle East & Africa (LAMEA).

North America is expected to account for largest share of the market owing to the high prevalence of the uterine cancer in the region. According to the national cancer institute, over 63,230 cases of uterine cancer were registered in 2018 in the U.S. Along with this, rising awareness regarding uterine cancer and subsequent treatment options is the other factor which is expected to forecast period 2019–2026.

Europe is expected to account for significant share of the global uterine cancer market owing to the presence of global major players in the region. According to the new research by Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, in the U.K, new cancer drug Tisotumab Vedotin (TV) has shown promising results when tested on drug resistant cancer patients and 7% of the endometrial cancer tumors stopped growing and started shrinking. Ongoing research and development regarding early diagnosis of the uterine cancer is expected to boost the market growth during the forecast period 2019–2026.

Asia Pacific uterine cancer market is forecasted to experience the fastest growth during the forecast period 2019–2026. Growth of Asia Pacific market is attributed to the constantly growing geriatric population and high prevalence of uterine cancer in the region. Availability of advanced diagnostic laboratories and improved healthcare infrastructure are some of the other factors expected to positively influence the market growth over the forecast period 2019–2026.

Latin America and the Middle East & Africa are expected to account for least share of the global uterine cancer market. Poor healthcare infrastructure in the Latin America and Low healthcare expenditure in Africa are the key factors for slow growth of the market.

Key Players

Some of the major players of the global uterine cancer market are Novartis AG, Merck & Company, Inc., R-Pharm-US LLC., Actiza Pharmaceutical Private Limited, Pfizer Inc., United Biotech Pvt Ltd, Bristol-Myers Squibb Company, Elder Pharmaceuticals Ltd, Par Pharmaceutical Companies, Inc., and AstraZeneca Plc.

Segmentation

By Type

  • Endometrial Adenocarcinoma
  • Adenosquamous Carcinoma
  • Papillary Serous Carcinoma
  • Uterine Sarcoma

By Treatment

  • Diagnosis
    • Pelvic Examination
    • Endometrial Biopsy
    • Transvaginal Ultrasound
    • Computed Tomography (CT or CAT) Scan
    • Magnetic Resonance Imaging (MRI)
  • Therapeutic Treatment
    • Radiation Therapy
    • Chemotherapy
    • Hormone Therapy
  • Surgery
    • Hysterectomy
    • Lymphadenectomy

By End User

  • Hospitals
  • Diagnostic Centers
  • Drug Stores
  • Online Pharmacies
  • Other End Users

By Region

  • North America (U.S. and Canada)
  • Europe (France, Italy, Germany and Rest of Europe)
  • Asia-Pacific (India, South Korea, China, Japan and Rest of Asia-Pacific)
  • LAMEA (Brazil, Turkey, Saudi Arabia, South Africa and Rest of LAMEA)

Why Buy This Report?

Researchers have introduced new treatment therapies for the treatment of advanced, recurrent, and metastatic endometrial cancer. Recently, immunotherapy has been introduced for treating uterine cancer which has shown improved results.

Our report covers the uterine cancer market insights, focusing on recent developments in the market in different regions and development strategies of the companies. Moreover, following sections are specifically covered in the report.

  • Definitive Market Data
  • Uterine Cancer Market Analysis
  • Recent Opportunities in the Market
  • 6-7 year performance forecasts: major segments covering onset type, treatment, end user, and regions
  • Market Share Analysis
  • Potential Venture Avenues
  • Pipeline Analysis


Request For Free Sample
Choose license Type

Buy Chapters or Sections

Avail customized purchase option to meet your exact research needs:

1)Buy sections of the report
2)Buy country level report
3)Request for historical data

Request a Free Sample   Special Pricing
Related Reports